[Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI'AN, CHINA August 14, 2009ystar Bio-Pharmaceuticalmpany (NASDAQ:BI) SECOND QUARTER 2009 & RECENT HIGHLIGHTS Revenuesreased 39.4% year-over-year to $6.2 million Gross margin improved to 52.6% from 51.6% in the second quarter of 2008ome from operationsreased by 37.6% year-over-year to $1.7 million]
[FORM 10-Q (Mark One) x o For the quarterly period ended June 30, 2009 OR o For the transition period from _________ to ___________ BTHC VIII, INC. Delaware 20-5463509 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) THT Industrial Park, No.5 Nanhuan Road, Tiexi District Siping, Jilin Province, China 136000 (Zip Code) 86-434-3265241 x o] [Section 302 of the Sarbanes-Oxley Act of 2002 I, Guohong Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BTHC VIII, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [I, Jianjun He, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BTHC VIII, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made,] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.]
